US8569052B2 - Oxygen depletion devices and methods for removing oxygen from red blood cells - Google Patents

Oxygen depletion devices and methods for removing oxygen from red blood cells Download PDF

Info

Publication number
US8569052B2
US8569052B2 US13/115,532 US201113115532A US8569052B2 US 8569052 B2 US8569052 B2 US 8569052B2 US 201113115532 A US201113115532 A US 201113115532A US 8569052 B2 US8569052 B2 US 8569052B2
Authority
US
United States
Prior art keywords
oxygen
hollow fibers
red blood
blood cells
cartridge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/115,532
Other versions
US20120100523A1 (en
Inventor
William J. Federspiel
Brian J. Frankowski
Tatsuro Yoshida
Paul J. Vernucci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Hemanext Inc
Original Assignee
University of Pittsburgh
New Health Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/115,532 priority Critical patent/US8569052B2/en
Application filed by University of Pittsburgh, New Health Sciences Inc filed Critical University of Pittsburgh
Assigned to UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION reassignment UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FEDERSPIEL, WILLIAM J., FRANKOWSKI, BRIAN J.
Assigned to NEW HEALTH SCIENCES, INC. reassignment NEW HEALTH SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VERNUCCI, PAUL J., YOSHIDA, TATSURO
Publication of US20120100523A1 publication Critical patent/US20120100523A1/en
Priority to US13/541,554 priority patent/US9199016B2/en
Priority to US14/038,001 priority patent/US9296990B2/en
Publication of US8569052B2 publication Critical patent/US8569052B2/en
Application granted granted Critical
Priority to US14/924,179 priority patent/US9844615B2/en
Priority to US15/811,481 priority patent/US10603417B2/en
Priority to US16/785,049 priority patent/US11433164B2/en
Priority to US17/872,127 priority patent/US20220355001A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0272—Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0208—Oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0429—Red blood cells; Erythrocytes

Definitions

  • the present invention relates to devices for depleting oxygen from red blood cells to enhance storage life.
  • the present invention relates to methods for depleting oxygen from red blood cells.
  • Adequate blood supply and the storage thereof is a problem facing every major hospital and health organization around the world. Often, the amount of blood supply in storage is considerably smaller than the need therefor. This is especially true during crisis periods such as natural catastrophes, war and the like, when the blood supply is often perilously close to running out. It is at critical times such as these that the cry for more donations of fresh blood is often heard. However, unfortunately, even when there is no crisis period, the blood supply and that kept in storage must be constantly monitored and replenished, because stored blood does not maintain its viability for long.
  • Hb hemoglobin
  • RBCs red blood cells
  • the present disclosure provides for a disposable device that is able to remove oxygen from red blood cells.
  • the present disclosure provides for an oxygen depletion device.
  • the device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers.
  • the hollow fibers are adapted to receiving and conveying red blood cells.
  • the present disclosure provides for an oxygen depletion device.
  • the device has a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas and a plurality of hollow fibers extending within the receptacle from an entrance to an exit thereof.
  • the hollow fibers are adapted to receiving and conveying red blood cells.
  • the present disclosure provides for a method for removing oxygen from red blood cells.
  • the method has the step of passing the red blood cells through an oxygen device.
  • the device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; and an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers.
  • the hollow fibers are adapted to receiving and conveying red blood cells
  • the present disclosure provides for a method for removing oxygen from red blood cells.
  • the method has the step of passing the red blood cells through an oxygen device.
  • the device has a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas; and a plurality of hollow fibers films extending within the receptacle from an entrance to an exit thereof.
  • the hollow fibers are adapted to receiving and conveying red blood cells.
  • FIG. 1 illustrates a pre-storage oxygen depletion device of the present invention.
  • FIG. 2 a illustrates an embodiment of a depletion device that depletes oxygen from red blood cells prior to storage by a flushing inert gas around a hollow fiber inside the assembly.
  • FIG. 2 b illustrates an embodiment of a depletion device that depletes oxygen from red blood cells prior to storage by a flushing inert gas around a hollow fiber inside the assembly.
  • FIG. 3 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
  • FIG. 3 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
  • FIG. 3 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
  • FIG. 4 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
  • FIG. 4 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
  • FIG. 4 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
  • FIG. 5 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
  • FIG. 5 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
  • FIG. 5 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
  • FIG. 6 illustrates a plot of flow rate of RBC suspension per minute versus oxygen partial pressure for the depletion devices of FIGS. 2 a through 2 c , FIGS. 3 a through 3 c , FIGS. 4 a through 4 c and FIGS. 5 a through 5 c.
  • an oxygen depletion device (ODD) 101 contains an oxygen sorbent 110 .
  • ODD 101 is a disposable cartridge 105 containing oxygen sorbent 110 and a series of hollow fibers 115 .
  • Oxygen sorbent 110 is a mixture of non-toxic inorganic and/or organic salts and ferrous iron or other materials with high reactivity toward oxygen.
  • Oxygen sorbent 110 is made from particles that have significant absorbing capacity for O 2 (more than 5 ml O 2 /g) and can maintain the inside of cartridge 105 to less than 0.01%, which corresponds to PO 2 less than 0.08 mmHg.
  • Oxygen sorbent 110 is either free or contained in an oxygen permeable envelope.
  • ODD 101 of the present disclosure can deplete approximately 100 mL of oxygen from a unit of blood.
  • RBCs pass through hollow porous fibers 115 .
  • Porous fibers are capable of high oxygen permeability rates. Suitable materials for porous fibers include polyolefins, TEFLON® (polytetrafluoroethylene), polyesters, polyvinylidene fluoride (PVDF), polysulfone, and other hydrophobic polymers as well as inorganic materials (ceramics).
  • Oxygen depletion takes place as RBCs pass through membrane 115 .
  • ODD provides a simple structure having a large surface area to remove oxygen and maintain constant flow of blood therethrough. The oxygen depletion or removal is accomplished by irreversible reaction of ferrous ion in oxygen sorbent 110 with ambient oxygen to form ferric oxide.
  • ODD 101 does not need agitation for oxygen removal and can be manufactured easily to withstand centrifugation as part of a blood collection system as necessary.
  • the depletion devices function to deplete O 2 by supplying appropriate composition of flushing gas.
  • Gases appropriate for depletion devices include, for example, Ar, He, CO 2 , N 2 .
  • FIGS. 4 a through 4 c and 5 a through 5 c also disclose scavenging depletion devices. Depletion takes place with the use of scavengers or sorbents and without the use of external gases. In both types of depletion devices however, oxygen depletion is effective to enhance DPG and ATP, respectively, prior to storage in blood storage bags.
  • Depletion device 20 includes a plurality of fibers 25 , approximately 5000 in number, through which red blood cells flow. Plurality of fibers 25 are surrounded by a plastic cylinder 30 . Plastic cylinder 30 contains a gas inlet 35 and a gas outlet 40 through which a flushing gas or a combination of flushing gases, such as those mentioned above, are supplied to remove oxygen from blood. Specifications for depletion device 20 are shown in Table 1 below.
  • Depletion device 45 like device 20 of FIGS. 2 a to 2 c , includes a plurality of fibers 50 , approximately 5000 in number, through which red blood cells flow. Plurality of fibers 50 are surrounded by a plastic cylinder 55 . Plastic cylinder 55 contains a gas inlet 60 and a gas outlet 65 through which a gas or a combination of gases, such as those mentioned above are supplied to remove oxygen from blood. Specifications for depletion device 45 are shown in Table 2 below. The active surface area of depletion of device 45 is twice that of device 20 because device 45 is twice as long as device 20 .
  • FIGS. 4 a through 4 c disclose a depletion device 70 having a core 75 containing scavenging materials for O 2 .
  • Core 75 is packed by a gas permeable film with very low liquid permeability.
  • Hollow fibers 80 are wound around core 75 , and a plastic cylinder 82 contains and envelopes hollow fibers 80 .
  • the active surface area for depletion is approximately 0.8796 m 2 as shown in Table 3 below.
  • FIGS. 5 a through 5 c disclose a depletion device 85 containing fiber bundles 87 enclosed in gas permeable film with very low liquid permeability. Fiber bundles 87 are surrounded by scavenger materials 89 for O 2 . Fiber bundles 87 and scavenger materials 89 are contained within a plastic cylinder 90 . The active surface area for depletion is approximately 0.8796 m 2 as shown in Table 4 below.
  • FIG. 6 is a plot of the performance of flushing depletion devices 20 and 45 and scavenging depletion devices 70 and 85 .
  • the data of FIG. 6 was plotted using the following conditions: Hematocrit, 62% (pooled 3 units of pRBC), and 21° C. at various head heights to produce different flow rates.
  • Oxygen scavenger Multisorb Technologies, Buffalo, N.Y.
  • Data are plotted with flow rate (g RBC suspension per min) vs. pO 2 (mmHg).
  • the hollow fibers may be packed in any suitable configuration within the cartridge, such as linear or longitudinal, spiral, or coil, so long as they can receive and convey red blood cells.
  • FIG. 6 shows that lowest oxygen saturation is achieved using devices 45 and 85 .
  • Device 45 exhibits a larger active surface area exposed to gases along length of fibers 50 .
  • Device 85 also has a long surface area of exposure to scavenging materials.
  • Device 85 has bundles 87 surrounded by scavenging materials 89 . The space occupied by scavenging materials 89 between bundles 87 promotes dispersion of oxygen from red blood cells contained in fiber bundles 87 , thus aiding scavenging of oxygen from red blood cells.
  • a further use of the depletion devices is to add back oxygen prior to transfusion by flushing with pure oxygen or air. This use is for special cases, such as massive transfusions, where the capacity of the lung to reoxygenate transfused blood is not adequate, or sickle cell anemia.
  • depletion devices can be used to obtain intermediate levels or states of depletion of oxygen depending needs of the patient to obtain optimal levels in the transfused blood depending upon the patients needs.
  • oxygen scavenger is a material that irreversibly binds to or combines with oxygen under the conditions of use.
  • oxygen can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound oxygen is zero can serve as an oxygen scavenger.
  • oxygen scavengers include iron powders and organic compounds.
  • oxygen sorbent may be used interchangeably herein with oxygen scavenger.
  • oxygen scavengers are provided by Multisorb Technologies (Buffalo, N.Y.). Such materials can be blended to a desired ratio to achieve desired results.
  • scavengers can be incorporated into storage receptacles and bags in any known form, such as in sachets, patches, coatings, pockets, and packets.

Abstract

An oxygen depletion device. The device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers. The hollow fibers are adapted to receiving and conveying red blood cells. There is another embodiment of an oxygen depletion device and method for removing oxygen from red blood cells.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a Continuation application of U.S. patent application Ser. No. 12/903,057, filed on Oct. 12, 2010 now abandoned, which claims priority based on U.S. Provisional Application No. 61/250,661, filed Oct. 12, 2009, both of which are incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made with government support under grants awarded by the National Institutes of Health (NIH) and the National Heart Lung and Blood Institute (NHLBI). The government has certain rights in the invention.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to devices for depleting oxygen from red blood cells to enhance storage life. The present invention relates to methods for depleting oxygen from red blood cells.
2. Background of the Art
Adequate blood supply and the storage thereof is a problem facing every major hospital and health organization around the world. Often, the amount of blood supply in storage is considerably smaller than the need therefor. This is especially true during crisis periods such as natural catastrophes, war and the like, when the blood supply is often perilously close to running out. It is at critical times such as these that the cry for more donations of fresh blood is often heard. However, unfortunately, even when there is no crisis period, the blood supply and that kept in storage must be constantly monitored and replenished, because stored blood does not maintain its viability for long.
Stored blood undergoes steady deterioration which is, in part, caused by hemoglobin oxidation and degradation and adenosine triphosphate (ATP) and 2-3,biphosphoglycerate (DPG) depletion. Oxygen causes hemoglobin (Hb) carried by the red blood cells (RBCs) to convert to met-Hb, the breakdown of which produces toxic products such as hemichrome, hemin and free Fe3+. Together with the oxygen, these products catalyze the formation of hydroxyl radicals (OH.cndot.), and both the OH.cndot. and the met-Hb breakdown products damage the red blood cell lipid membrane, the membrane skeleton, and the cell contents. As such, stored blood is considered unusable after 6 weeks, as determined by the relative inability of the red blood cells to survive in the circulation of the transfusion recipient. The depletion of DPG prevents adequate transport of oxygen to tissue thereby lowering the efficacy of transfusion immediately after administration (levels of DPG recover once in recipient after 8-48 hrs). In addition, these deleterious effects also result in reduced overall efficacy and increased side effects of transfusion therapy with stored blood before expiration date, but possibly older than two weeks are used.
There is, therefore, a need to be able to deplete oxygen levels in red blood cells prior to storage on a long-term basis without the stored blood undergoing the harmful effects caused by the oxygen and hemoglobin interaction.
SUMMARY OF THE INVENTION
Accordingly, the present disclosure provides for a disposable device that is able to remove oxygen from red blood cells.
The present disclosure provides for an oxygen depletion device. The device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers. The hollow fibers are adapted to receiving and conveying red blood cells.
The present disclosure provides for an oxygen depletion device. The device has a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas and a plurality of hollow fibers extending within the receptacle from an entrance to an exit thereof. The hollow fibers are adapted to receiving and conveying red blood cells.
The present disclosure provides for a method for removing oxygen from red blood cells. The method has the step of passing the red blood cells through an oxygen device. The device has a cartridge; a plurality of hollow fibers extending within the cartridge from an entrance to an exit thereof; and an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers. The hollow fibers are adapted to receiving and conveying red blood cells
The present disclosure provides for a method for removing oxygen from red blood cells. The method has the step of passing the red blood cells through an oxygen device. The device has a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas; and a plurality of hollow fibers films extending within the receptacle from an entrance to an exit thereof. The hollow fibers are adapted to receiving and conveying red blood cells.
The present disclosure and its features and advantages will become more apparent from the following detailed description with reference to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates a pre-storage oxygen depletion device of the present invention.
FIG. 2 a illustrates an embodiment of a depletion device that depletes oxygen from red blood cells prior to storage by a flushing inert gas around a hollow fiber inside the assembly.
FIG. 2 b illustrates an embodiment of a depletion device that depletes oxygen from red blood cells prior to storage by a flushing inert gas around a hollow fiber inside the assembly.
FIG. 2 c illustrates an embodiment of a depletion device that depletes oxygen from red blood cells prior to storage by a flushing inert gas around a hollow fiber inside the assembly.
FIG. 3 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
FIG. 3 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
FIG. 3 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage.
FIG. 4 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
FIG. 4 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
FIG. 4 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells prior to storage wherein oxygen is scavenged by scavenger materials in the core of the cylinder, surrounded by hollow fibers.
FIG. 5 a illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
FIG. 5 b illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
FIG. 5 c illustrates another embodiment of a depletion device that depletes oxygen from red blood cells wherein oxygen is scavenged by scavenger materials surrounding cylinders of hollow fibers.
FIG. 6 illustrates a plot of flow rate of RBC suspension per minute versus oxygen partial pressure for the depletion devices of FIGS. 2 a through 2 c, FIGS. 3 a through 3 c, FIGS. 4 a through 4 c and FIGS. 5 a through 5 c.
DETAILED DESCRIPTION OF THE DISCLOSURE
Referring to FIG. 2, an oxygen depletion device (ODD) 101 contains an oxygen sorbent 110. ODD 101 is a disposable cartridge 105 containing oxygen sorbent 110 and a series of hollow fibers 115. Oxygen sorbent 110 is a mixture of non-toxic inorganic and/or organic salts and ferrous iron or other materials with high reactivity toward oxygen. Oxygen sorbent 110 is made from particles that have significant absorbing capacity for O2 (more than 5 ml O2/g) and can maintain the inside of cartridge 105 to less than 0.01%, which corresponds to PO2 less than 0.08 mmHg. Oxygen sorbent 110 is either free or contained in an oxygen permeable envelope. ODD 101 of the present disclosure can deplete approximately 100 mL of oxygen from a unit of blood.
RBCs pass through hollow porous fibers 115. Porous fibers are capable of high oxygen permeability rates. Suitable materials for porous fibers include polyolefins, TEFLON® (polytetrafluoroethylene), polyesters, polyvinylidene fluoride (PVDF), polysulfone, and other hydrophobic polymers as well as inorganic materials (ceramics). Oxygen depletion takes place as RBCs pass through membrane 115. ODD provides a simple structure having a large surface area to remove oxygen and maintain constant flow of blood therethrough. The oxygen depletion or removal is accomplished by irreversible reaction of ferrous ion in oxygen sorbent 110 with ambient oxygen to form ferric oxide. ODD 101 does not need agitation for oxygen removal and can be manufactured easily to withstand centrifugation as part of a blood collection system as necessary.
Referring to FIGS. 2 a through 2 c and FIGS. 3 a through 3 c, examples of flushing depletion devices are disclosed. The depletion devices function to deplete O2 by supplying appropriate composition of flushing gas. Gases appropriate for depletion devices include, for example, Ar, He, CO2, N2.
FIGS. 4 a through 4 c and 5 a through 5 c, also disclose scavenging depletion devices. Depletion takes place with the use of scavengers or sorbents and without the use of external gases. In both types of depletion devices however, oxygen depletion is effective to enhance DPG and ATP, respectively, prior to storage in blood storage bags.
Referring to FIGS. 2 a through 2 c, a depletion device 20 is shown. Depletion device 20 includes a plurality of fibers 25, approximately 5000 in number, through which red blood cells flow. Plurality of fibers 25 are surrounded by a plastic cylinder 30. Plastic cylinder 30 contains a gas inlet 35 and a gas outlet 40 through which a flushing gas or a combination of flushing gases, such as those mentioned above, are supplied to remove oxygen from blood. Specifications for depletion device 20 are shown in Table 1 below.
TABLE 1
Eternal Gas External Gas
Prototype Specification Pathways Pathways
Prototype Serial #: Device 20
Fiber Type: Celgard Celgard
200/150-66FPI 200/150-66FPI
Number of Fibers: 5000 5000
Active Length of Fibers (cm): 13 28
Fiber OD (microns): 200 200
Fiber ID (microns): 150 150
Total Length of Fibers: 15 30
Active Fiber Surface Area (m2): 0.4084 0.8796
Referring to FIGS. 3 a through 3 c, a depletion device 45 is shown. Depletion device 45, like device 20 of FIGS. 2 a to 2 c, includes a plurality of fibers 50, approximately 5000 in number, through which red blood cells flow. Plurality of fibers 50 are surrounded by a plastic cylinder 55. Plastic cylinder 55 contains a gas inlet 60 and a gas outlet 65 through which a gas or a combination of gases, such as those mentioned above are supplied to remove oxygen from blood. Specifications for depletion device 45 are shown in Table 2 below. The active surface area of depletion of device 45 is twice that of device 20 because device 45 is twice as long as device 20.
TABLE 2
Eternal Gas External Gas
Prototype Specification Pathways Pathways
Prototype Serial #: Device 45
Fiber Type: Celgard Celgard
200/150-66FPI 200/150-66FPI
Number of Fibers: 5000 5000
Active Length of Fibers (cm): 13 28
Fiber OD (microns): 200 200
Fiber ID (microns): 150 150
Total Length of Fibers: 15 30
Active Fiber Surface Area (m2): 0.4084 0.8796
FIGS. 4 a through 4 c disclose a depletion device 70 having a core 75 containing scavenging materials for O2. Core 75 is packed by a gas permeable film with very low liquid permeability. Hollow fibers 80 are wound around core 75, and a plastic cylinder 82 contains and envelopes hollow fibers 80. In this particular embodiment, the active surface area for depletion is approximately 0.8796 m2 as shown in Table 3 below.
TABLE 3
Center Core 10 individual
125 grams Bundles 200 grams
Prototype Specification Sorbent Sorbent
Prototype Serial #: Device 70
Fiber Type: Celgard Celgard
200/150-66FPI 200/150-66FPI
Number of Fibers: 5000 5000
Active Length of Fibers (cm): 13 28
Fiber OD (microns): 200 200
Fiber ID (microns): 150 150
Total Length of Fibers 15 30
Active Fiber Surface Area (m2): 0.8796 0.8796
FIGS. 5 a through 5 c disclose a depletion device 85 containing fiber bundles 87 enclosed in gas permeable film with very low liquid permeability. Fiber bundles 87 are surrounded by scavenger materials 89 for O2. Fiber bundles 87 and scavenger materials 89 are contained within a plastic cylinder 90. The active surface area for depletion is approximately 0.8796 m2 as shown in Table 4 below.
TABLE 4
Center Core 10 individual
125 grams Bundles 200 grams
Prototype Specification Sorbent Sorbent
Prototype Serial #: Device 85
Fiber Type: Celgard Celgard
200/150-66FPI 200/150-66FPI
Number of Fibers: 5000 5000
Active Length of Fibers (cm): 13 28
Fiber OD (microns): 200 200
Fiber ID (microns): 150 150
Total Length of Fibers 15 30
Active Fiber Surface Area (m2): 0.8796 0.8796
FIG. 6 is a plot of the performance of flushing depletion devices 20 and 45 and scavenging depletion devices 70 and 85. The data of FIG. 6 was plotted using the following conditions: Hematocrit, 62% (pooled 3 units of pRBC), and 21° C. at various head heights to produce different flow rates. Oxygen scavenger (Multisorb Technologies, Buffalo, N.Y.) was activated with adding 5% and 12% w/w water vapor for device 79 and device 85, respectively. Data are plotted with flow rate (g RBC suspension per min) vs. pO2 (mmHg).
In the oxygen depletion devices disclosed herein, the hollow fibers may be packed in any suitable configuration within the cartridge, such as linear or longitudinal, spiral, or coil, so long as they can receive and convey red blood cells.
FIG. 6 shows that lowest oxygen saturation is achieved using devices 45 and 85. Device 45 exhibits a larger active surface area exposed to gases along length of fibers 50. Device 85 also has a long surface area of exposure to scavenging materials. Device 85 has bundles 87 surrounded by scavenging materials 89. The space occupied by scavenging materials 89 between bundles 87 promotes dispersion of oxygen from red blood cells contained in fiber bundles 87, thus aiding scavenging of oxygen from red blood cells.
A further use of the depletion devices is to add back oxygen prior to transfusion by flushing with pure oxygen or air. This use is for special cases, such as massive transfusions, where the capacity of the lung to reoxygenate transfused blood is not adequate, or sickle cell anemia.
Similarly, depletion devices can be used to obtain intermediate levels or states of depletion of oxygen depending needs of the patient to obtain optimal levels in the transfused blood depending upon the patients needs.
It is within the scope of the present invention to remove oxygen from the RBCs or to strip oxygen from the blood prior to storage in the storage bags. An oxygen scavenger can be used to remove the oxygen from the RBCs prior to storage in the blood bags. As used herein, “oxygen scavenger” is a material that irreversibly binds to or combines with oxygen under the conditions of use. For example, the oxygen can chemically react with some component of the material and be converted into another compound. Any material where the off-rate of bound oxygen is zero can serve as an oxygen scavenger. Examples of oxygen scavengers include iron powders and organic compounds. The term “oxygen sorbent” may be used interchangeably herein with oxygen scavenger. For example, oxygen scavengers are provided by Multisorb Technologies (Buffalo, N.Y.). Such materials can be blended to a desired ratio to achieve desired results.
It will be appreciated that scavengers can be incorporated into storage receptacles and bags in any known form, such as in sachets, patches, coatings, pockets, and packets.
Although the present invention describes in detail certain embodiments, it is understood that variations and modifications exist known to those skilled in the art that are within the invention. Accordingly, the present invention is intended to encompass all such alternatives, modifications and variations that are within the scope of the invention as set forth in the disclosure.

Claims (17)

What is claimed is:
1. An oxygen depletion device comprising:
a cartridge;
a plurality of hollow fibers extending within said cartridge from an entrance to an exit thereof, wherein the hollow fibers are formed of an oxygen-permeable membrane and are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger packed within the cartridge and contiguous to and in between the plurality of hollow fibers, wherein said red blood cells are passaged within said hollow fibers.
2. The device of claim 1, wherein said hollow fibers are substantially parallel and longitudinally disposed within the cartridge from said entrance to said exit.
3. The oxygen depletion device of claim 1, wherein said oxygen scavenger is ferrous iron.
4. The oxygen depletion device of claim 1, wherein said plurality of hollow fibers are formed from an oxygen-permeable material selected from the group consisting of polyolefin, polytetrafluoroethylene, polyester, polvvinylidene fluoride (PVDF), and polysulfone.
5. The oxygen depletion device of claim 1, wherein said plurality of hollow fibers are formed from a hydrophobic polymer.
6. The oxygen depletion device of claim 1, wherein said plurality of hollow fibers are formed from an inorganic ceramic.
7. The oxygen depletion device of claim 1, wherein said plurality of hollow fibers are configured as a linear spiral, a longitudinal spiral, or a coil.
8. An oxygen depletion device comprising:
a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas;
a plurality of hollow fibers extending within the receptacle from an entrance to an exit thereof; wherein the hollow fibers are adapted to receiving and conveying red blood cells, wherein said red blood cells are passaged within said hollow fibers.
9. The device of claim 8, wherein the hollow fibers are substantially parallel and longitudinally disposed within the cartridge from said entrance to said exit.
10. The device of claim 8, further including a source of flushing gas in communication with said inlet of said receptacle.
11. A method for removing oxygen from red blood cells comprising:
passing red blood cells through an oxygen depletion device, wherein the device comprises:
a cartridge;
a plurality of hollow fibers extending within said cartridge from an entrance to an exit thereof, wherein said plurality of hollow fibers are adapted to receiving and conveying red blood cells; and
an amount of an oxygen scavenger packed within said cartridge and contiguous to and in between said plurality of hollow fibers, wherein said red blood cells are passaged within said hollow fibers.
12. The method of claim 11, wherein said oxygen scavenger is ferrous iron.
13. The method of claim 11, wherein said plurality of hollow fibers are formed from an oxygen-permeable material selected from the group consisting of polyolefin, polytetrafluoroethylene, polyester, polvvinylidene fluoride (PVDF), and polysulfone.
14. The method of claim 11, wherein said plurality of hollow fibers are formed from a hydrophobic polymer.
15. The method of claim 11, wherein said plurality of hollow fibers are formed from an inorganic ceramic.
16. The method of claim 11, wherein said plurality of hollow fibers are configured as a linear spiral, a longitudinal spiral, or a coil.
17. A method for removing oxygen from red blood cells comprising:
passing the red blood cells through an oxygen depletion device, wherein the device comprises:
a receptacle of a solid material having an inlet and an outlet adapted to receiving and expelling a flushing gas;
a plurality of hollow fibers extending within the receptacle from an entrance to an exit thereof, wherein the hollow fibers are adapted to receiving and conveying red blood cells, wherein said red blood cells are passaged within said hollow fibers.
US13/115,532 2009-10-12 2011-05-25 Oxygen depletion devices and methods for removing oxygen from red blood cells Active US8569052B2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/115,532 US8569052B2 (en) 2009-10-12 2011-05-25 Oxygen depletion devices and methods for removing oxygen from red blood cells
US13/541,554 US9199016B2 (en) 2009-10-12 2012-07-03 System for extended storage of red blood cells and methods of use
US14/038,001 US9296990B2 (en) 2009-10-12 2013-09-26 Oxygen depletion devices and methods for removing oxygen from red blood cells
US14/924,179 US9844615B2 (en) 2009-10-12 2015-10-27 System for extended storage of red blood cells and methods of use
US15/811,481 US10603417B2 (en) 2009-10-12 2017-11-13 System for extended storage of red blood cells and methods of use
US16/785,049 US11433164B2 (en) 2009-10-12 2020-02-07 System for extended storage of red blood cells and methods of use
US17/872,127 US20220355001A1 (en) 2009-10-12 2022-07-25 System for Extended Storage of Red Blood Cells and Methods of Use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25066109P 2009-10-12 2009-10-12
US90305710A 2010-10-12 2010-10-12
US13/115,532 US8569052B2 (en) 2009-10-12 2011-05-25 Oxygen depletion devices and methods for removing oxygen from red blood cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US90305710A Continuation 2009-10-12 2010-10-12

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US12/901,350 Continuation-In-Part US8535421B2 (en) 2009-10-12 2010-10-08 Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US13/289,722 Continuation-In-Part US10136635B2 (en) 2009-10-12 2011-11-04 Irradiation of red blood cells and anaerobic storage
US13/541,554 Continuation-In-Part US9199016B2 (en) 2009-10-12 2012-07-03 System for extended storage of red blood cells and methods of use
US14/038,001 Continuation US9296990B2 (en) 2009-10-12 2013-09-26 Oxygen depletion devices and methods for removing oxygen from red blood cells

Publications (2)

Publication Number Publication Date
US20120100523A1 US20120100523A1 (en) 2012-04-26
US8569052B2 true US8569052B2 (en) 2013-10-29

Family

ID=43876489

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/115,532 Active US8569052B2 (en) 2009-10-12 2011-05-25 Oxygen depletion devices and methods for removing oxygen from red blood cells
US14/038,001 Active 2031-07-21 US9296990B2 (en) 2009-10-12 2013-09-26 Oxygen depletion devices and methods for removing oxygen from red blood cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/038,001 Active 2031-07-21 US9296990B2 (en) 2009-10-12 2013-09-26 Oxygen depletion devices and methods for removing oxygen from red blood cells

Country Status (9)

Country Link
US (2) US8569052B2 (en)
EP (1) EP2389064A4 (en)
JP (1) JP2013507447A (en)
CN (1) CN102905522A (en)
AU (1) AU2010306920A1 (en)
BR (1) BR112012008682A2 (en)
CA (1) CA2781874A1 (en)
NZ (1) NZ599890A (en)
WO (1) WO2011046963A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150129493A1 (en) * 2012-06-15 2015-05-14 University of Pittsburgh-of The Commonweath System of Higher Education Devices, systems and methods for reducing the concentration of carbon dioxide in blood
US9801784B2 (en) 2015-04-23 2017-10-31 New Health Sciences, Inc. Anaerobic blood storage containers
US9844615B2 (en) 2009-10-12 2017-12-19 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US9877476B2 (en) 2013-02-28 2018-01-30 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
US9968718B2 (en) 2011-03-28 2018-05-15 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US10058091B2 (en) 2015-03-10 2018-08-28 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US10065134B2 (en) 2010-05-05 2018-09-04 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
US10136635B2 (en) 2010-05-05 2018-11-27 New Health Sciences, Inc. Irradiation of red blood cells and anaerobic storage
US10251387B2 (en) 2010-08-25 2019-04-09 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
US10583192B2 (en) 2016-05-27 2020-03-10 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method
US11013771B2 (en) 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US11583615B2 (en) 2017-12-28 2023-02-21 I-Sep System and method for treating haemorrhagic fluid for autotransfusion

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702557A (en) 2011-03-16 2014-04-02 梅奥医学教育和研究基金会 Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
WO2015054378A1 (en) * 2013-10-08 2015-04-16 Drexel University Novel microfluidic devices for diagnosing red blood cells abnormalities, and methods using same
KR102405257B1 (en) * 2015-01-28 2022-06-03 삼성디스플레이 주식회사 Display device
US11662353B2 (en) 2020-09-10 2023-05-30 Functional Fluidics Inc. Method for assessing the effects of hypoxia on tissues

Citations (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1044649A (en) 1964-05-08 1966-10-05 Schwarz Biores Inc Improvements in or relating to the preservation of blood
US4086924A (en) 1976-10-06 1978-05-02 Haemonetics Corporation Plasmapheresis apparatus
US4228032A (en) 1978-11-06 1980-10-14 Dow Corning Corporation Method of storing blood and a blood storage bag therefore
WO1981002239A1 (en) 1980-02-05 1981-08-20 Baxter Travenol Lab Red cell storage solution
US4300559A (en) 1978-10-26 1981-11-17 Baxter Travenol Laboratories, Inc. Blood compatible polymers and medical devices made therefrom
US4370160A (en) 1978-06-27 1983-01-25 Dow Corning Corporation Process for preparing silicone microparticles
US4381775A (en) 1980-02-05 1983-05-03 Takeda Chemical Industries, Ltd. Method for low pressure filtration of plasma from blood
EP0100419A2 (en) 1982-07-07 1984-02-15 Biotest Aktiengesellschaft Aqueous solution for suspending and storing cells, particularly erythrocytes
US4540416A (en) 1983-08-18 1985-09-10 El Paso Polyolefins Company Heat-sterilizable polyolefin compositions and articles manufactured therefrom
WO1986000809A1 (en) 1984-07-19 1986-02-13 American National Red Cross Prolonged storage of red blood cells
FR2581289A1 (en) 1985-05-06 1986-11-07 Rgl Transfusion Sanguine Centr SYNTHETIC SOLUTION FOR THE EXTENDED STORAGE OF ERYTHROCYTA CONCENTRATES
US4654053A (en) 1984-07-27 1987-03-31 University Patents, Inc. Oxygen sorbent
EP0217759A1 (en) 1985-09-24 1987-04-08 SORIN BIOMEDICA S.p.A. Improvements in hollow-fibre oxygenators for blood
US4670013A (en) 1982-12-27 1987-06-02 Miles Laboratories, Inc. Container for blood and blood components
US4701267A (en) 1984-03-15 1987-10-20 Asahi Medical Co., Ltd. Method for removing leukocytes
US4713176A (en) 1985-04-12 1987-12-15 Hemascience Laboratories, Inc. Plasmapheresis system and method
US4748121A (en) 1984-11-30 1988-05-31 Ppg Industries, Inc. Porous glass fibers with immobilized biochemically active material
US4769318A (en) 1986-06-03 1988-09-06 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4769175A (en) 1985-06-26 1988-09-06 Mitsubishi Gas Chemical Company, Inc. Sheet-like, oxygen-scavenging agent
EP0299381A2 (en) 1987-07-11 1989-01-18 Dainippon Ink And Chemicals, Inc. Membrane-type artificial lung and method of using it
DE3722984A1 (en) 1987-07-11 1989-01-19 Biotest Pharma Gmbh AQUEOUS SOLUTION FOR SUSPENDING AND STORING CELLS, ESPECIALLY ERYTHROCYTES
WO1989002274A1 (en) 1987-09-21 1989-03-23 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4837047A (en) 1984-07-16 1989-06-06 Sumitomo Bakelite Co., Ltd. Container and method for storing blood
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US4880786A (en) 1987-01-14 1989-11-14 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4902701A (en) 1982-04-27 1990-02-20 Burroughs Welcome Co. Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US5000848A (en) 1987-01-28 1991-03-19 Membrex, Inc. Rotary filtration device with hyperphilic membrane
WO1991004659A1 (en) 1989-10-06 1991-04-18 American National Red Cross Procedure for storing red cells with prolonged maintenance of cellular concentrations of atp and 2,3 dpg
US5023054A (en) 1988-11-11 1991-06-11 Hitachi, Ltd. Blood filter and apparatus for hemorheological measurement
US5037419A (en) 1989-09-21 1991-08-06 Eastman Kodak Company Blood bag system containing vitamin E
SU1718766A1 (en) 1990-01-30 1992-03-15 Ленинградский научно-исследовательский институт гематологии и переливания крови Method for preserving the blood erythrocytes
WO1992008348A1 (en) 1990-11-07 1992-05-29 Baxter International Inc. Red blood cell storage solution
US5152905A (en) 1989-09-12 1992-10-06 Pall Corporation Method for processing blood for human transfusion
US5192320A (en) 1987-07-11 1993-03-09 Dainippon Ink And Chemicals Inc. Artificial lung and method of using it
US5208335A (en) 1991-03-19 1993-05-04 Air Products And Chemicals, Inc. Reversible oxygen sorbent compositions
US5229012A (en) 1989-05-09 1993-07-20 Pall Corporation Method for depletion of the leucocyte content of blood and blood components
US5254248A (en) 1990-06-28 1993-10-19 Terumo Kabushiki Kaisha Blood plasma separating apparatus
US5353793A (en) 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5356375A (en) 1992-04-06 1994-10-18 Namic U.S.A. Corporation Positive pressure fluid delivery and waste removal system
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US5386014A (en) 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
US5387624A (en) 1991-12-26 1995-02-07 Dow Corning Toray Silicon Co., Ltd. Method for the preparation of a powder mixture composed of cured silicone microparticles and inorganic microparticles
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5427663A (en) 1993-06-08 1995-06-27 British Technology Group Usa Inc. Microlithographic array for macromolecule and cell fractionation
US5443743A (en) 1991-09-11 1995-08-22 Pall Corporation Gas plasma treated porous medium and method of separation using same
WO1995029662A2 (en) 1994-04-20 1995-11-09 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5506141A (en) 1982-05-10 1996-04-09 Bar-Ilan University Apertured cell carrier
US5529821A (en) 1992-06-29 1996-06-25 Terumo Kabushiki Kaisha Container for storing blood or blood component
WO1996029864A1 (en) 1995-03-24 1996-10-03 Organ, Inc. Rejuvenating outdated red cells
US5617873A (en) 1994-08-25 1997-04-08 The United States Of America As Represented By The Administrator, Of The National Aeronautics And Space Administration Non-invasive method and apparatus for monitoring intracranial pressure and pressure volume index in humans
US5624794A (en) 1995-06-05 1997-04-29 The Regents Of The University Of California Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US5635358A (en) 1992-05-01 1997-06-03 Trustees Of The University Of Pennsylvania Fluid handling methods for use in mesoscale analytical devices
US5691452A (en) 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
US5693230A (en) 1996-01-25 1997-12-02 Gas Research Institute Hollow fiber contactor and process
US5698250A (en) 1996-04-03 1997-12-16 Tenneco Packaging Inc. Modifield atmosphere package for cut of raw meat
JP2700170B2 (en) 1987-07-11 1998-01-19 大日本インキ化学工業株式会社 Membrane oxygenator
US5730989A (en) 1995-02-16 1998-03-24 Novavax, Inc. Oral vaccine against gram negative bacterial infection
US5750115A (en) 1989-08-03 1998-05-12 Akzo Nobel N. V. Escherichia coli vaccine
US5783148A (en) 1994-03-14 1998-07-21 Becton Dickinson And Company Nucleic acid amplification method and apparatus
US5783094A (en) 1995-04-13 1998-07-21 Teva Medical Ltd. Whole blood and platelet leukocyte filtration method
US5789151A (en) 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US5846427A (en) 1995-10-23 1998-12-08 Hemasure, Inc. Extra-lumenal crossflow plasmapheresis devices and method of use thereof
EP0890368A1 (en) 1997-07-09 1999-01-13 SIS-TER S.p.A. Blood treatment apparatus
WO1999048963A2 (en) 1998-03-25 1999-09-30 Chevron Phillips Chemical Company Lp Oxygen scavengers with reduced oxidation products for use in plastic films and beverage and food containers
US5972710A (en) 1996-03-29 1999-10-26 University Of Washington Microfabricated diffusion-based chemical sensor
US6027623A (en) 1998-04-22 2000-02-22 Toyo Technologies, Inc. Device and method for electrophoretic fraction
US6047203A (en) 1997-03-17 2000-04-04 Nims, Inc. Physiologic signs feedback system
US6090062A (en) 1998-05-29 2000-07-18 Wayne State University Programmable antisiphon shunt system
US6150085A (en) 1998-09-16 2000-11-21 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells and composition
US6162396A (en) 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6210601B1 (en) 1999-04-21 2001-04-03 Larry A. Hottle Method of making an oxygen scavenging sealant composition
US6231770B1 (en) 1996-07-09 2001-05-15 Pall Corporation Multiple element filter and method of using therefor
US6254628B1 (en) 1996-12-09 2001-07-03 Micro Therapeutics, Inc. Intracranial stent
US20010027156A1 (en) 1999-06-03 2001-10-04 Yair Egozy Core for blood processing apparatus
US6337026B1 (en) 1999-03-08 2002-01-08 Whatman Hemasure, Inc. Leukocyte reduction filtration media
US6368871B1 (en) 1997-08-13 2002-04-09 Cepheid Non-planar microstructures for manipulation of fluid samples
US6387461B1 (en) 1999-05-06 2002-05-14 Cryovac, Inc. Oxygen scavenger compositions
US20020062078A1 (en) 2000-09-29 2002-05-23 Kevin Crutchfield Decision support systems and methods for assessing vascular health
US20020066699A1 (en) 1998-07-08 2002-06-06 Boggs Daniel R. Composite membranes and methods for making such membranes
US6403124B1 (en) 1997-04-16 2002-06-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US20020086329A1 (en) 2000-12-29 2002-07-04 Igor Shvets Biological assays
US20020085952A1 (en) 2000-09-27 2002-07-04 Ellingboe Bruce S. Blood perfusion system
US20020099570A1 (en) 2000-08-24 2002-07-25 Knight Stephen C. Recruiting a patient into a clinical trial
US6439577B2 (en) 1997-05-20 2002-08-27 Zymequest, Inc. Rotating seals for cell processing systems
JP2002253936A (en) 2001-02-28 2002-09-10 Japan Gore Tex Inc Separation membrane tube and separation membrane module
US6447987B1 (en) 1978-09-09 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells
US6468732B1 (en) 2000-04-04 2002-10-22 Bayer Corporation Method and long-term stable bicarbonate-containing diluent composition, and storage means therefor, for reducing or reversing aeration induced cell shrinkage and storage induced cell swelling of a whole blood sample
US6475147B1 (en) 1999-01-27 2002-11-05 The United States Of America As Represented By The United States National Aeronautics And Space Administration Ultrasonic apparatus and technique to measure changes in intracranial pressure
US6482585B2 (en) 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US20020182241A1 (en) 2001-01-02 2002-12-05 Borenstein Jeffrey T. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
US20030003575A1 (en) 1999-04-30 2003-01-02 Vacanti Joseph P. Fabrication of vascularized tissue using microfabricated two-dimensional molds
US6527957B1 (en) 1995-08-09 2003-03-04 Baxter International Inc. Methods for separating, collecting and storing red blood cells
US6564207B1 (en) 1998-11-02 2003-05-13 Ahmed A. Abdoh Method for automated data collection, analysis and reporting
WO2003043571A2 (en) 2001-11-16 2003-05-30 Hollinger Digital, Inc. Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation
US20030124504A1 (en) 2001-11-16 2003-07-03 Bitensky Mark W. Additive solution for blood preservation
US6610772B1 (en) 1999-08-10 2003-08-26 Eastman Chemical Company Platelet particle polymer composite with oxygen scavenging organic cations
US20030183801A1 (en) 2002-03-28 2003-10-02 Hu Yang Porous oxygen scavenging material
US20030189003A1 (en) 2002-04-08 2003-10-09 Menahem Kraus Leukocyte filter construction
US6688476B2 (en) 1993-12-22 2004-02-10 Baxter International Inc. Filter assembly having a flexible housing and method of making same
US20040026341A1 (en) 2002-04-16 2004-02-12 Niclas Hogberg Blood component processing system, apparatus, and method
US6695803B1 (en) 1998-10-16 2004-02-24 Mission Medical, Inc. Blood processing system
US6697667B1 (en) 2001-05-31 2004-02-24 Advanced Cardiovascular Systems, Inc. Apparatus and method for locating coronary sinus
US6761695B2 (en) 2002-03-07 2004-07-13 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for non-invasive measurement of changes in intracranial pressure
US6773407B2 (en) 2002-04-08 2004-08-10 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Non-invasive method of determining absolute intracranial pressure
US20040168982A1 (en) 2003-03-01 2004-09-02 Hemanext, L.L.C. Microvascular network device
US6817979B2 (en) 2002-06-28 2004-11-16 Nokia Corporation System and method for interacting with a user's virtual physiological model via a mobile terminal
US20050038342A1 (en) 2000-09-29 2005-02-17 New Health Sciences, Inc. Systems and methods for using dynamic vascular assessment to improve vascular stent placement, application, design and marketing
US6866783B2 (en) * 2000-03-07 2005-03-15 Mat Adsorption Technologies Gmbh & Co. Kg Module with membrane elements in cross-flow and in a dead-end arrangement
US20050137517A1 (en) 2003-12-19 2005-06-23 Baxter International Inc. Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation
US20050139806A1 (en) 2003-12-24 2005-06-30 Havens Marvin R. Oxygen scavenger compositions
US6955648B2 (en) 2000-09-29 2005-10-18 New Health Sciences, Inc. Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound
US20050230856A1 (en) 2002-03-19 2005-10-20 Parekh Bipin S Hollow fiber membrane contact apparatus and process
US20050233302A1 (en) 2004-02-18 2005-10-20 Hess John R Compositions and methods for the storage of red blood cells
US20060081524A1 (en) 2004-10-15 2006-04-20 Amitava Sengupta Membrane contactor and method of making the same
WO2006057473A1 (en) 2004-11-23 2006-06-01 Newheart Bio Co., Ltd. Filter module with multi-function parts for a blood purification and/or oxygenation using thereof and method for a blood purification and oxygenation and purification device comprising thereof
US20060118479A1 (en) 2004-08-24 2006-06-08 Shevkoplyas Sergey S Particle separating devices, systems, and methods
US7104958B2 (en) 2001-10-01 2006-09-12 New Health Sciences, Inc. Systems and methods for investigating intracranial pressure
US20070078113A1 (en) 2005-04-20 2007-04-05 Roth Mark B Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
US7208120B2 (en) 2000-09-27 2007-04-24 The Trustees Of Boston University Cellular diagnostic arrays, methods of using and processing for producing same
US20070240569A1 (en) 2005-05-09 2007-10-18 Nitto Denko Corporation Degasifier
US7347887B2 (en) 2003-12-22 2008-03-25 The Boc Group, Inc. Oxygen sorbent compositions and methods of using same
US7361277B2 (en) 1999-03-16 2008-04-22 Pall Corporation Biological fluid filter and system
US20080243045A1 (en) 2003-10-03 2008-10-02 Medical Service S.R.L Apparatus and method for the treatment of blood
US7431995B2 (en) 2001-04-17 2008-10-07 Baxter International Inc. Multiple layer polymeric structure
US7452601B2 (en) 2003-08-28 2008-11-18 Cryovac, Inc. Oxygen scavenger compositions derived from isophthalic acid/or terephthalic acid monomer or derivatives thereof
US20090017128A1 (en) 2001-08-01 2009-01-15 Battelle Memorial Institute Carbon dioxide removal from whole blood by photolytic activation
US20090269837A1 (en) 2003-03-01 2009-10-29 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
US7721898B2 (en) 2001-07-31 2010-05-25 Asahi Kasei Medical Co., Ltd. Coating material for leukocyte removal filter and the filter
US7754798B2 (en) 2003-08-28 2010-07-13 Cryovac, Inc. Oxygen scavenger block copolymers and compositions
US7775376B2 (en) 2003-01-24 2010-08-17 Fresenius Hemocare Italia S.R.L. Filter for the separation of leukocytes from whole blood or blood preparations, method for production of said filter, corresponding device and use thereof
US20100221697A1 (en) 2005-01-12 2010-09-02 BioVec Transfusions, LLC Composition for preserving platelets and method of using and storing the same
US20100313755A1 (en) 2009-06-11 2010-12-16 Georgia Tech Research Corporation Fiber sorbents
WO2011014855A2 (en) 2009-07-31 2011-02-03 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Removal of oxygen from biological fluids
US20120024156A1 (en) 2009-10-12 2012-02-02 New Health Sciences, Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US20120219633A1 (en) 2011-02-28 2012-08-30 Pall Corporation Removal of immunoglobulins and leukocytes from biological fluids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58194879U (en) 1982-06-17 1983-12-24 三菱電機株式会社 electron beam welding machine
JPS6363616A (en) 1986-09-04 1988-03-22 Showa Denko Kk Preservation agent for concentrated erythrocyte liquid and method for preservation
JPH07121340B2 (en) 1987-07-11 1995-12-25 大日本インキ化学工業株式会社 Hollow fiber membrane
JP3177713B2 (en) 1992-04-30 2001-06-18 科学技術振興事業団 How to store blood for transfusion or blood products
US6045701A (en) 1994-10-17 2000-04-04 Baxter International Inc. Method of filtering a fluid suspension with a membrane having a particular coating
EP1211261A3 (en) 1995-03-23 2004-03-17 Biopure Corporation Stable polymerized hemoglobin blood-substitute
US5605934A (en) 1995-03-23 1997-02-25 Baxter International Inc. Method of manufacturing and storing solutions
SE9601348D0 (en) 1996-04-10 1996-04-10 Pharmacia Ab Improved containers for parenteral fluids
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
US6582496B1 (en) 2000-01-28 2003-06-24 Mykrolis Corporation Hollow fiber membrane contactor
JP2004089495A (en) 2002-08-30 2004-03-25 Terumo Corp Bag link
US20080160107A1 (en) 2002-09-10 2008-07-03 Nitric Biotherapeutics, Inc. Use of nitric oxide gas to treat blood and blood products
DE10327988B4 (en) 2002-12-18 2009-05-14 Alpha Plan Gmbh Filter module for the treatment of liquids
CN2894710Y (en) 2006-03-31 2007-05-02 天津市海河医院 Medical blood-qi exchanger
US9339025B2 (en) 2010-08-25 2016-05-17 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
CA2817106C (en) 2010-11-05 2020-08-25 Paul Vernucci Irradiation of red blood cells and anaerobic storage
US9174771B2 (en) 2013-03-15 2015-11-03 Sangart, Inc. Packaging system for preserving a nonoxygenated hemoglobin based oxygen therapeutic product

Patent Citations (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1044649A (en) 1964-05-08 1966-10-05 Schwarz Biores Inc Improvements in or relating to the preservation of blood
US4086924A (en) 1976-10-06 1978-05-02 Haemonetics Corporation Plasmapheresis apparatus
US4370160A (en) 1978-06-27 1983-01-25 Dow Corning Corporation Process for preparing silicone microparticles
US6447987B1 (en) 1978-09-09 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells
US4300559A (en) 1978-10-26 1981-11-17 Baxter Travenol Laboratories, Inc. Blood compatible polymers and medical devices made therefrom
US4228032A (en) 1978-11-06 1980-10-14 Dow Corning Corporation Method of storing blood and a blood storage bag therefore
WO1981002239A1 (en) 1980-02-05 1981-08-20 Baxter Travenol Lab Red cell storage solution
US4381775A (en) 1980-02-05 1983-05-03 Takeda Chemical Industries, Ltd. Method for low pressure filtration of plasma from blood
US4902701A (en) 1982-04-27 1990-02-20 Burroughs Welcome Co. Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof
US5506141A (en) 1982-05-10 1996-04-09 Bar-Ilan University Apertured cell carrier
US4572899A (en) 1982-07-07 1986-02-25 Biotest-Serum-Institut Gmbh Aqueous solution for suspending and storing cells, especially erthrocytes
EP0100419A2 (en) 1982-07-07 1984-02-15 Biotest Aktiengesellschaft Aqueous solution for suspending and storing cells, particularly erythrocytes
US4670013A (en) 1982-12-27 1987-06-02 Miles Laboratories, Inc. Container for blood and blood components
US4540416A (en) 1983-08-18 1985-09-10 El Paso Polyolefins Company Heat-sterilizable polyolefin compositions and articles manufactured therefrom
US4701267B1 (en) 1984-03-15 1996-03-12 Asahi Medical Co Method for removing leukocytes
US4701267A (en) 1984-03-15 1987-10-20 Asahi Medical Co., Ltd. Method for removing leukocytes
US5417986A (en) 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US4837047A (en) 1984-07-16 1989-06-06 Sumitomo Bakelite Co., Ltd. Container and method for storing blood
US4585735A (en) 1984-07-19 1986-04-29 American National Red Cross Prolonged storage of red blood cells
WO1986000809A1 (en) 1984-07-19 1986-02-13 American National Red Cross Prolonged storage of red blood cells
US4654053A (en) 1984-07-27 1987-03-31 University Patents, Inc. Oxygen sorbent
US4748121A (en) 1984-11-30 1988-05-31 Ppg Industries, Inc. Porous glass fibers with immobilized biochemically active material
US4713176A (en) 1985-04-12 1987-12-15 Hemascience Laboratories, Inc. Plasmapheresis system and method
FR2581289A1 (en) 1985-05-06 1986-11-07 Rgl Transfusion Sanguine Centr SYNTHETIC SOLUTION FOR THE EXTENDED STORAGE OF ERYTHROCYTA CONCENTRATES
US4769175A (en) 1985-06-26 1988-09-06 Mitsubishi Gas Chemical Company, Inc. Sheet-like, oxygen-scavenging agent
EP0217759A1 (en) 1985-09-24 1987-04-08 SORIN BIOMEDICA S.p.A. Improvements in hollow-fibre oxygenators for blood
US4749551A (en) 1985-09-24 1988-06-07 Sorin Biomedica S.P.A. Hollow-fiber oxygenators for blood
US4769318A (en) 1986-06-03 1988-09-06 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4880786A (en) 1987-01-14 1989-11-14 Ube Industries, Ltd. Additive solution for blood preservation and activation
US5000848A (en) 1987-01-28 1991-03-19 Membrex, Inc. Rotary filtration device with hyperphilic membrane
JP2700170B2 (en) 1987-07-11 1998-01-19 大日本インキ化学工業株式会社 Membrane oxygenator
EP0299381A2 (en) 1987-07-11 1989-01-18 Dainippon Ink And Chemicals, Inc. Membrane-type artificial lung and method of using it
DE3722984A1 (en) 1987-07-11 1989-01-19 Biotest Pharma Gmbh AQUEOUS SOLUTION FOR SUSPENDING AND STORING CELLS, ESPECIALLY ERYTHROCYTES
US5192320A (en) 1987-07-11 1993-03-09 Dainippon Ink And Chemicals Inc. Artificial lung and method of using it
WO1989002274A1 (en) 1987-09-21 1989-03-23 American Red Cross Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets
US4925572A (en) 1987-10-20 1990-05-15 Pall Corporation Device and method for depletion of the leukocyte content of blood and blood components
US4880548A (en) 1988-02-17 1989-11-14 Pall Corporation Device and method for separating leucocytes from platelet concentrate
US5023054A (en) 1988-11-11 1991-06-11 Hitachi, Ltd. Blood filter and apparatus for hemorheological measurement
US5229012A (en) 1989-05-09 1993-07-20 Pall Corporation Method for depletion of the leucocyte content of blood and blood components
US5750115A (en) 1989-08-03 1998-05-12 Akzo Nobel N. V. Escherichia coli vaccine
US5152905A (en) 1989-09-12 1992-10-06 Pall Corporation Method for processing blood for human transfusion
US5037419A (en) 1989-09-21 1991-08-06 Eastman Kodak Company Blood bag system containing vitamin E
WO1991004659A1 (en) 1989-10-06 1991-04-18 American National Red Cross Procedure for storing red cells with prolonged maintenance of cellular concentrations of atp and 2,3 dpg
US5386014A (en) 1989-11-22 1995-01-31 Enzon, Inc. Chemically modified hemoglobin as an effective, stable, non-immunogenic red blood cell substitute
SU1718766A1 (en) 1990-01-30 1992-03-15 Ленинградский научно-исследовательский институт гематологии и переливания крови Method for preserving the blood erythrocytes
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5254248A (en) 1990-06-28 1993-10-19 Terumo Kabushiki Kaisha Blood plasma separating apparatus
WO1992008348A1 (en) 1990-11-07 1992-05-29 Baxter International Inc. Red blood cell storage solution
US5208335A (en) 1991-03-19 1993-05-04 Air Products And Chemicals, Inc. Reversible oxygen sorbent compositions
US5443743A (en) 1991-09-11 1995-08-22 Pall Corporation Gas plasma treated porous medium and method of separation using same
US5353793A (en) 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5387624A (en) 1991-12-26 1995-02-07 Dow Corning Toray Silicon Co., Ltd. Method for the preparation of a powder mixture composed of cured silicone microparticles and inorganic microparticles
US5356375A (en) 1992-04-06 1994-10-18 Namic U.S.A. Corporation Positive pressure fluid delivery and waste removal system
US5635358A (en) 1992-05-01 1997-06-03 Trustees Of The University Of Pennsylvania Fluid handling methods for use in mesoscale analytical devices
US5529821A (en) 1992-06-29 1996-06-25 Terumo Kabushiki Kaisha Container for storing blood or blood component
US5427663A (en) 1993-06-08 1995-06-27 British Technology Group Usa Inc. Microlithographic array for macromolecule and cell fractionation
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US6688476B2 (en) 1993-12-22 2004-02-10 Baxter International Inc. Filter assembly having a flexible housing and method of making same
US5783148A (en) 1994-03-14 1998-07-21 Becton Dickinson And Company Nucleic acid amplification method and apparatus
WO1995029662A2 (en) 1994-04-20 1995-11-09 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US5617873A (en) 1994-08-25 1997-04-08 The United States Of America As Represented By The Administrator, Of The National Aeronautics And Space Administration Non-invasive method and apparatus for monitoring intracranial pressure and pressure volume index in humans
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5730989A (en) 1995-02-16 1998-03-24 Novavax, Inc. Oral vaccine against gram negative bacterial infection
US5691452A (en) 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
WO1996029864A1 (en) 1995-03-24 1996-10-03 Organ, Inc. Rejuvenating outdated red cells
US5783094A (en) 1995-04-13 1998-07-21 Teva Medical Ltd. Whole blood and platelet leukocyte filtration method
US5624794A (en) 1995-06-05 1997-04-29 The Regents Of The University Of California Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US6527957B1 (en) 1995-08-09 2003-03-04 Baxter International Inc. Methods for separating, collecting and storing red blood cells
US5846427A (en) 1995-10-23 1998-12-08 Hemasure, Inc. Extra-lumenal crossflow plasmapheresis devices and method of use thereof
US5693230A (en) 1996-01-25 1997-12-02 Gas Research Institute Hollow fiber contactor and process
US5972710A (en) 1996-03-29 1999-10-26 University Of Washington Microfabricated diffusion-based chemical sensor
US5811142A (en) 1996-04-03 1998-09-22 Tenneo Packaging Modified atmosphere package for cut of raw meat
US5698250A (en) 1996-04-03 1997-12-16 Tenneco Packaging Inc. Modifield atmosphere package for cut of raw meat
US6231770B1 (en) 1996-07-09 2001-05-15 Pall Corporation Multiple element filter and method of using therefor
US6254628B1 (en) 1996-12-09 2001-07-03 Micro Therapeutics, Inc. Intracranial stent
US6047203A (en) 1997-03-17 2000-04-04 Nims, Inc. Physiologic signs feedback system
US6482585B2 (en) 1997-04-16 2002-11-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6403124B1 (en) 1997-04-16 2002-06-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Storage and maintenance of blood products including red blood cells and platelets
US6162396A (en) 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
JP2000516963A (en) 1997-05-15 2000-12-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Erythrocyte long-term preservation method using oxygen removal and additives
US5789151A (en) 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US6439577B2 (en) 1997-05-20 2002-08-27 Zymequest, Inc. Rotating seals for cell processing systems
EP0890368A1 (en) 1997-07-09 1999-01-13 SIS-TER S.p.A. Blood treatment apparatus
US6368871B1 (en) 1997-08-13 2002-04-09 Cepheid Non-planar microstructures for manipulation of fluid samples
WO1999048963A2 (en) 1998-03-25 1999-09-30 Chevron Phillips Chemical Company Lp Oxygen scavengers with reduced oxidation products for use in plastic films and beverage and food containers
US6027623A (en) 1998-04-22 2000-02-22 Toyo Technologies, Inc. Device and method for electrophoretic fraction
US6090062A (en) 1998-05-29 2000-07-18 Wayne State University Programmable antisiphon shunt system
US20020066699A1 (en) 1998-07-08 2002-06-06 Boggs Daniel R. Composite membranes and methods for making such membranes
US6150085A (en) 1998-09-16 2000-11-21 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells and composition
US6695803B1 (en) 1998-10-16 2004-02-24 Mission Medical, Inc. Blood processing system
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
US6564207B1 (en) 1998-11-02 2003-05-13 Ahmed A. Abdoh Method for automated data collection, analysis and reporting
US6475147B1 (en) 1999-01-27 2002-11-05 The United States Of America As Represented By The United States National Aeronautics And Space Administration Ultrasonic apparatus and technique to measure changes in intracranial pressure
US6337026B1 (en) 1999-03-08 2002-01-08 Whatman Hemasure, Inc. Leukocyte reduction filtration media
US20030062299A1 (en) 1999-03-08 2003-04-03 Whatman Hemasure, Inc. Leukocyte reduction filtration media
US7361277B2 (en) 1999-03-16 2008-04-22 Pall Corporation Biological fluid filter and system
US6210601B1 (en) 1999-04-21 2001-04-03 Larry A. Hottle Method of making an oxygen scavenging sealant composition
US20030003575A1 (en) 1999-04-30 2003-01-02 Vacanti Joseph P. Fabrication of vascularized tissue using microfabricated two-dimensional molds
US6387461B1 (en) 1999-05-06 2002-05-14 Cryovac, Inc. Oxygen scavenger compositions
US20010027156A1 (en) 1999-06-03 2001-10-04 Yair Egozy Core for blood processing apparatus
US6610772B1 (en) 1999-08-10 2003-08-26 Eastman Chemical Company Platelet particle polymer composite with oxygen scavenging organic cations
US6866783B2 (en) * 2000-03-07 2005-03-15 Mat Adsorption Technologies Gmbh & Co. Kg Module with membrane elements in cross-flow and in a dead-end arrangement
US6468732B1 (en) 2000-04-04 2002-10-22 Bayer Corporation Method and long-term stable bicarbonate-containing diluent composition, and storage means therefor, for reducing or reversing aeration induced cell shrinkage and storage induced cell swelling of a whole blood sample
US20020099570A1 (en) 2000-08-24 2002-07-25 Knight Stephen C. Recruiting a patient into a clinical trial
US20020085952A1 (en) 2000-09-27 2002-07-04 Ellingboe Bruce S. Blood perfusion system
US7208120B2 (en) 2000-09-27 2007-04-24 The Trustees Of Boston University Cellular diagnostic arrays, methods of using and processing for producing same
US20020062078A1 (en) 2000-09-29 2002-05-23 Kevin Crutchfield Decision support systems and methods for assessing vascular health
US20050038342A1 (en) 2000-09-29 2005-02-17 New Health Sciences, Inc. Systems and methods for using dynamic vascular assessment to improve vascular stent placement, application, design and marketing
US6955648B2 (en) 2000-09-29 2005-10-18 New Health Sciences, Inc. Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound
US6723051B2 (en) 2000-09-29 2004-04-20 New Health Sciences, Inc. Systems and methods for assessing vascular health
US20020086329A1 (en) 2000-12-29 2002-07-04 Igor Shvets Biological assays
US20020182241A1 (en) 2001-01-02 2002-12-05 Borenstein Jeffrey T. Tissue engineering of three-dimensional vascularized using microfabricated polymer assembly technology
JP2002253936A (en) 2001-02-28 2002-09-10 Japan Gore Tex Inc Separation membrane tube and separation membrane module
US7431995B2 (en) 2001-04-17 2008-10-07 Baxter International Inc. Multiple layer polymeric structure
US6697667B1 (en) 2001-05-31 2004-02-24 Advanced Cardiovascular Systems, Inc. Apparatus and method for locating coronary sinus
US7721898B2 (en) 2001-07-31 2010-05-25 Asahi Kasei Medical Co., Ltd. Coating material for leukocyte removal filter and the filter
US20090017128A1 (en) 2001-08-01 2009-01-15 Battelle Memorial Institute Carbon dioxide removal from whole blood by photolytic activation
US7104958B2 (en) 2001-10-01 2006-09-12 New Health Sciences, Inc. Systems and methods for investigating intracranial pressure
WO2003043571A2 (en) 2001-11-16 2003-05-30 Hollinger Digital, Inc. Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation
US8071282B2 (en) 2001-11-16 2011-12-06 The Trustees Of Boston University Method of storing red blood cells with an acidic additive solution under oxygen depletion
US7723017B2 (en) 2001-11-16 2010-05-25 The Trustees Of Boston University Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation
US20050208462A1 (en) 2001-11-16 2005-09-22 Hemanext Llc Additive solution for blood preservation
JP2005535279A (en) 2001-11-16 2005-11-24 ホリンガー・ディジタル・インコーポレイテッド A method for extending the effective shelf life of refrigerated red blood cells by nutritional supplementation
US20030124504A1 (en) 2001-11-16 2003-07-03 Bitensky Mark W. Additive solution for blood preservation
US6761695B2 (en) 2002-03-07 2004-07-13 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for non-invasive measurement of changes in intracranial pressure
US20050230856A1 (en) 2002-03-19 2005-10-20 Parekh Bipin S Hollow fiber membrane contact apparatus and process
US20030183801A1 (en) 2002-03-28 2003-10-02 Hu Yang Porous oxygen scavenging material
US6773407B2 (en) 2002-04-08 2004-08-10 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Non-invasive method of determining absolute intracranial pressure
US20030189003A1 (en) 2002-04-08 2003-10-09 Menahem Kraus Leukocyte filter construction
US20040026341A1 (en) 2002-04-16 2004-02-12 Niclas Hogberg Blood component processing system, apparatus, and method
US6817979B2 (en) 2002-06-28 2004-11-16 Nokia Corporation System and method for interacting with a user's virtual physiological model via a mobile terminal
US7775376B2 (en) 2003-01-24 2010-08-17 Fresenius Hemocare Italia S.R.L. Filter for the separation of leukocytes from whole blood or blood preparations, method for production of said filter, corresponding device and use thereof
US20090269837A1 (en) 2003-03-01 2009-10-29 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
US20040168982A1 (en) 2003-03-01 2004-09-02 Hemanext, L.L.C. Microvascular network device
US7452601B2 (en) 2003-08-28 2008-11-18 Cryovac, Inc. Oxygen scavenger compositions derived from isophthalic acid/or terephthalic acid monomer or derivatives thereof
US7754798B2 (en) 2003-08-28 2010-07-13 Cryovac, Inc. Oxygen scavenger block copolymers and compositions
US20080243045A1 (en) 2003-10-03 2008-10-02 Medical Service S.R.L Apparatus and method for the treatment of blood
US20050137517A1 (en) 2003-12-19 2005-06-23 Baxter International Inc. Processing systems and methods for providing leukocyte-reduced blood components conditioned for pathogen inactivation
US7347887B2 (en) 2003-12-22 2008-03-25 The Boc Group, Inc. Oxygen sorbent compositions and methods of using same
US20050139806A1 (en) 2003-12-24 2005-06-30 Havens Marvin R. Oxygen scavenger compositions
US20120129148A1 (en) 2004-02-18 2012-05-24 Hess John R Compositions and methods for the storage of red blood cells
US20050233302A1 (en) 2004-02-18 2005-10-20 Hess John R Compositions and methods for the storage of red blood cells
US20060118479A1 (en) 2004-08-24 2006-06-08 Shevkoplyas Sergey S Particle separating devices, systems, and methods
US20060081524A1 (en) 2004-10-15 2006-04-20 Amitava Sengupta Membrane contactor and method of making the same
WO2006057473A1 (en) 2004-11-23 2006-06-01 Newheart Bio Co., Ltd. Filter module with multi-function parts for a blood purification and/or oxygenation using thereof and method for a blood purification and oxygenation and purification device comprising thereof
KR100721054B1 (en) 2004-11-23 2007-05-25 주식회사 뉴하트바이오 Filter module with multi-function parts for a blood purification and/or oxygenation using thereof and method for a blood purification and oxygenation and purification device comprising thereof
US20100221697A1 (en) 2005-01-12 2010-09-02 BioVec Transfusions, LLC Composition for preserving platelets and method of using and storing the same
US20070078113A1 (en) 2005-04-20 2007-04-05 Roth Mark B Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
US20070240569A1 (en) 2005-05-09 2007-10-18 Nitto Denko Corporation Degasifier
US20100313755A1 (en) 2009-06-11 2010-12-16 Georgia Tech Research Corporation Fiber sorbents
WO2011014855A2 (en) 2009-07-31 2011-02-03 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Removal of oxygen from biological fluids
US20120024156A1 (en) 2009-10-12 2012-02-02 New Health Sciences, Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US20120219633A1 (en) 2011-02-28 2012-08-30 Pall Corporation Removal of immunoglobulins and leukocytes from biological fluids

Non-Patent Citations (108)

* Cited by examiner, † Cited by third party
Title
Alcantar et al., "Polyethylene glycol-coated biocompatible surfaces," Journal of Biomedical Materials Research, 51(3):343-351 (2000).
Anderson et al., "Microfabrication and microfluidics for tissue engineering: state of the art and future opportunities," Lab Chip, 4:98-103 (2004).
Barbee et al., "The Fahraeus Effect," Microvascular Research, 3:6-16 (1971).
Barclay et al., "A Method for Detecting Chaos in Canine Myocardial Microcirculatory Red Cell Flux," Microcirculation, 7(5):335-346 (2000).
Bardy et al., "Technetium-99m Labeling by Means of Stannous Pyrophosphate: Application to Bleomycin and Red Blood Cells," Journal of Nuclear Medicine, 16(5):435-437 (1975).
Barras et al., "Einfluss der Rejuvenation auf die rheologischen Eigenschaften gelagerter Erythrozyten," VASA, 23(4):305-311 (1994).
Beutler et al., "Storage of red cell concentrates in CPD-A2 for 42 and 49 days," The Journal of Laboratory and Clinical Medicine, 102(1):53-62 (1983).
Borenstein et al., "Microfabrication Technology for Vascularized Tissue Engineering," Biomedical Microdevices, 4(3):167-175 (2002).
Brody et al., "Deformation and Flow of Red Blood Cells in a Synthetic Lattice: Evidence for an Active Cytoskeleton," Biophysical Journal, 68:2224-2232 (1995).
Carmen, "The Selection of Plastic Materials for Blood Bags," Transfusion Medicine Reviews, 7(1):1-10 (1993).
Carr et al., "Nonlinear Dynamics of Microvascular Blood Flow," Annals of Biomedical Engineering, 28:641-652 (2000).
Cell Deformability, RheoSCAN (RheoScan-AnD300/RheoScan-D300), obtained on Dec. 11, 2012, from: http://www.rheoscan.com/products/products/products-01.html.
Chilton et al., "Privacy Protection of Health Information: Patient Rights and Pediatrician Responsibilities," Pediatrics, 104(4):973-977 (1999).
Cokelet et al., "Fabrication of in Vitro Microvascular Blood Flow Systems by Photolithography," Microvascular Research, 46:394-400 (1993).
Dale et al., "Human Vaccination with Escherichia coli J5 Mutant Induces Cross-Reactive Bactericidal Antibody against Neisseria gonorrhoeae Lipooligosaccharide," The Journal of Infectious Diseases, 166:316-325 (1992).
De Angelis et al., "Erythrocyte Shape Control in Stored Blood: The Effect of Additive Solutions on Shape Recovery," Haematologica, 73:7-12 (1988).
De Venuto et al. "Rejuvenation of Human Red Blood Cells During Liquid Storage," Transfusion, 14(4):338-344 (1974).
Deible et al., "Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol," Biomaterials, 19:1885-1893 (1998).
Dumaswala et al., "Glutamine- and Phosphate-Containing Hypotonic Storage Media Better Maintain Erythrocyte Membrane Physical Properties," Blood, 88(2):697-704 (1996).
Dumaswala et al., "Improved Red Blood Cell Preservation Correlates With Decreased Loss of Bands 3, 4.1, Acetylcholinestrase, and Lipids in Microvesicles," Blood, 87(4):1612-1616 (1996).
Dumaswala et al., "Studies in Red Blood Cell Preservation: 9. The Role of Glutamine in Red Cell Preservation," Vox Sang, 67:255-259 (1994).
Dumont et al., "Anaerobic storage of red blood cells in a novel additive solution improves in vivo recovery," Transfusion, 49(3):458-464 (2009).
Effenhauser et al., "Integrated Capillary Electrophoresis on Flexible Silicone Microdevices: Analysis of DNA Restriction Fragments and Detection of Single DNA Molecules on Microchips," Anal. Chem., 69:3451-3457 (1997).
European Search Report completed on Feb. 11, 2005, in European Patent Application No. 02 78 2307.9.
Fahraeus et al., "The Viscosity of the Blood in Narrow Capillary Tubes," Am. J. Physiol., 96(3):562-568 (1931).
Fang et al., "Inhibition of Lipopolysaccharide-Associated Endotoxin Activities In Vitro and In Vivo by the Human Anti-Lipid A Monoclonal Antibody SdJ5-1.17.15," Infection and Immunity, 61(9):3873-3878 (1993).
Frame et al., "A System for Culture of Endothelial Cells in 20-50-mum Branching Tubes," Microcirculation, 2 (4):377-385 (1995).
Frame et al., "A System for Culture of Endothelial Cells in 20-50-μm Branching Tubes," Microcirculation, 2 (4):377-385 (1995).
Fung et al., "High-Resolution Data on the Geometry of Red Blood Cells", Biorheology, 18:369-385 (1981).
Gañán-Calvo et al., "Current and Droplet Size in the Electrospraying of Liquids. Scaling Laws," J. Aerosol Sci., 28(2):249-275 (1997).
Green et al., "10. Liposomal Vaccines," Immunobiology of Proteins and Peptides VII, Plenum Press, New York, pp. 83-92 (1995).
Greenwalt et al., "Studies in red blood cell preservation. 10. 51Cr Recovery of Red Cells after Liquid Storage in a Glycerol-Containing Additive Solution," Vox Sang, 70:6-10 (1996).
Greenwalt et al., "Studies in Red Blood Cell Preservation. 7. In vivo and in Vitro Studies with a Modified Phosphate-Ammonium Additive Solution," Vox Sang, 65:87-94 (1993).
Greenwalt et al., "Studies in Red Blood Cell Preservation. 8. Liquid Storage of Red Cells in Glycerol-Containing Additive Solution," Vox. Sang, 67:139-143 (1994).
Greenwalt et al., "The effect of hypotonicity, glutamine, and glycine on red cell preservation," Transfusion, 37:269-276 (1997).
Griffith, "Temporal chaos in the microcirculation," Cardiovascular Research, 31:342-358 (1996).
Hamasaki et al., "Acid-citrate-dextrose-phosphoenolpyruvate medium as a rejuvenant for blood storage," Transfusion, 23(1):1-7 (1983).
Hess et al., "Successful storage of RBCs for 9 weeks in a new additive solution," Transfusion, 40:1007-1011 (2000).
Hess, "Extended Liquid Storage of Red Blood Cells," Blood Donors and the Supply of Blood and Blood Products, National Academy Press, Washington, D.C., pp. 99-102 (1996).
Hess, "Storage of red blood cells under anaerobic conditions," Vox Sanguinis, 93:183 (2007).
Hodgson et al., "Prophylactic use of human endotoxin-core hyperimmune gammaglobulin to prevent endotoxaemia in colostrum-deprived, gnotobiotic lambs challenged orally with Escherichia coli," FEMS Immunology and Medical Microbiology, 11:171-180 (1995).
Högman et al., "Cell Shape and Total Adenylate Concentration as Important Factors for Posttransfusion Survival of Erythrocytes," Biomed. Biochim. Acta, 42:S327-S331 (1983).
Högman et al., "Effects of Oxygen and Mixing on red cells stored in plastic bags at +4° C," Biomed. Biochim. Acta., 46:S290-S294 (1987).
Högman et al., "Shall Red Cell Units Stand Upright, Lie Flat or be Mixed During Storage? In Vitro Studies of Red Cells Collected in 0.5 CPD and Stored in RAS2 (Erythrosol®)," Transfus. Sci., 16(2):193-199 (1995).
Högman et al.,"Effects of Oxygen on Red Cells during Liquid Storage at +4° C," Vox Sang., 51:27-34 (1986).
Huang et al., "Continuous Particle Separation Through Deterministic Lateral Displacement," Science, 304:987-990 (2004).
International Preliminary Report on Patentability completed on Feb. 14, 2012, in International Patent Application No. PCT/US2010/52084.
International Preliminary Report on Patentability completed on May 21, 2012, in International Patent Application No. PCT/US2010/52376.
International Preliminary Report on Patentability completed on Oct. 18, 2011, in International Patent Application No. PCT/US2010/031055.
International Preliminary Report on Patentability Dated May 24, 2012 From Corresponding PCT Application No. PCT/US2010/52376.
International Search Report and Written Opinion dated Apr. 27, 2011 for corresponding International Patent Application No. PCT/US2010/044045.
International Search Report and Written Opinion dated Dec. 6, 2010 for corresponding International Patent Application No. PCT/US2010/052376.
International Search Report and Written Opinion dated Feb. 18, 2011 for corresponding International Patent Application No. PCT/US2010/052084.
International Search Report completed on Apr. 26, 2011, in International Patent Application No. PCT/US2010/044045.
International Search Report completed on Dec. 21, 2011, in International Patent Application No. PCT/US11/49168.
International Search Report completed on Feb. 12, 2012, in International Patent Application No. PCT/US11/59372.
International Search Report completed on Jul. 8, 1996, in International Patent Application No. PCT/US96/09005.
International Search Report completed on Jun. 18, 2012, in International Patent Application No. PCT/US12/30930.
International Search Report completed on May 20, 2010, in International Patent Application No. PCT/US2010/31055.
International Search Report completed on Nov. 10, 2003, in International Patent Application No. PCT/US02/36735.
International Search Report completed on Sep. 24, 2012, in International Patent Application No. PCT/US12/50380.
Jain, et al., "Determinants of Leukocyte Margination in Rectangular Microchannels," PLoS ONE, 4(9):1-8 (2009).
Jayasinghe et al., "Controlled deposition of nanoparticle clusters by electrohydrodynamic atomization," Nanotechnology, 15:1519-1523 (2004).
Jiang et al., "Microfluidic synthesis of monodisperse PDMS microbeads as discrete oxygen sensors," Soft Matter, 8:923-926 (2011).
Jo et al., "Surface modification using silanated poly(ethylene glycol)s," Biomaterials, 21:605-616 (2000).
Johnson et al., "Regulation of blood flow in single capillaries," American Journal of Physiology, 212:1405-1415 (1967).
Kaihara et al., "Silicon Micromachining to Tissue Engineer Branched Vascular Channels for Liver Fabrication," Tissue Engineering, 6(2):105-117 (2000).
Kiani et al., "Fluctuations in microvascular blood flow parameters caused by hemodynamic mechanisms," American Journal of Physiology, 266(5):H1822-H1828 (1994).
Kikuchi et al., "Modified Cell-Flow Microchannels in a Single-Crystal Silicon Substrate and Flow Behavior of Blood Cells," Microvascular Research, 47:126-139 (1994).
Koch et al., "Duration of Red-Cell Storage and Complications After Cardiac Surgery," The New England Journal of Medicine, 358:1229-1239 (2008).
Koch et al., "Peripheral blood leukocyte NO production and oxidative stress in multiple sclerosis," Multiple Sclerosis, 14:159-165 (2008).
Krogh, "Studies on the physiology of capillaries. II. The reactions to local stimuli of the blood-vessels in the skin and web of the frog," The Journal of Physiology, 55:412-422 (1921).
Kuraoka, et al., "Ship-in-a-bottle synthesis of a cobalt phthalocyanine/porous glass composite membrane for oxygen separation," Journal of Membrane Science, 286(1-2):12-14 (2006).
Lugowski et al., "Anti-endotoxin antibodies directed against Escherichia coli R-1 oligosaccharide core-tetanus toxoid conjugate bind to smooth, live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity," FEMS Immunology and Medical Microbiology, 16:31-38 (1996).
Mazor et al., "Prolonged Storage of Red Cells: The Effect of pH, Adenine Phosphate," Vox Sanguinis, 66:264-269 (1994).
McDonald et al., "Poly(dimethylsiloxane) as a Material for Fabricating Microfluidic Devices," Accounts of Chemical Research, 35(7):491-499 (2002).
Meryman et al., "Extending the storage of red cells at 4° C," Transfus. Sci., 15(2):105-115 (1994).
Meryman et al., "Prolonged storage of red cells at 4° C," Transfusion, 26(6):500-505 (1986).
Moll et al., "Dean vortices applied to membrane process. Part II: Numerical approach," Journal of Membrane Science, 288:321-335 (2007).
Moroff et al., "Proposed standardization of methods for determining the 24-hour survival of stored red cells," Transfusion, 24:109-114 (1984).
Murphy et al., "Increased Mortality, Postoperative Morbidity, and Cost After Red Blood Cell Transfusion in Patients Having Cardiac Surgery," Circulation, 116:2544-2552 (2007).
Ng et al., "Components for integrated poly(dimethylsiloxane) microfluidic systems," Electrophoresis, 23:3461-3473 (2002).
Ohkuma et al., "The preservative-exchange method using a sextuple-bag system for a 10-week storage period of red blood cells," Transfusion Medicine, 1:257-262 (1991).
Poxton, "Antibodies to lipopolysaccharide," Journal of Immunological Methods, 186:1-15 (1995).
Pries et al., "Biophysical aspects of blood flow in the microvasculature," Cardiovascular Research, 32:654-667 (1996).
Sambuceti et al., "Why should we study the coronary microcirculation?," Am J Physiol Heart Circ Physiol, 279:H2581-H2584 (2000).
Shevkoplyas et al., "Direct measurement of the impact of impaired erythrocyte deformability on microvascular network perfusion in a microfluidic device," Lab Chip, 6:914-920 (2006).
Shimizu et al., "Multicenter Clinical Evaluation of Red Cell Concentrates Stored up to 6 Weeks in MAP, a new additive solution," Japanese Journal of Clinical Hematology, 33(2):148-156 (1992).
Skalak et al., "Deformation of Red Blood Cell in Capillaries," Science, 164(3880):717-719 (1969).
Sohmer et al., "Phosphoenolypyruvate (PEP) Effects on Fresh and Stored Red Blood Cells," Proceedings of the Society for Experimental Biology and Medicine, 171:24-33 (1982).
Sutton et al., "A Novel Instrument for Studying the Flow Behaviour of Erythrocytes through Microchannels Simulating Human Blood Capillaries," Microvascular Research, 53:272-281 (1997).
Szymanski et al., "Effect of rejuvenation and frozen storage on 42-day-old AS-1 RBCs," Transfusion, 41:550-555 (2001).
The International Committee for Standardization in Hematology, "Recommended Methods for Radioisotope Red Cell Survival Studies," Blood, 38(3):378-386 (1971).
Tinmouth et al., "The Clinical Consequences of the Red Cell Storage Lesion," Transfusion Medicine Reviews, 15(2):91-107 (2001).
Tracey et al., "A Silicon Micromachined Device for Use in Blood Cell Deformability Studies," IEEE Transactions on Biomedical Engineering, 42(8):751-761 (1995).
Tsukada et al., "Direct Measurement of Erythrocyte Deformability in Diabetes Mellitus with a Transparent Microchannel Capillary Model and High-Speed Video Camera System," Microvascular Research, 61:231-239 (2001).
Valeri et al., "The survival, function, and hemolysis of human RBCs stored at 4° C in additive solution (AS-1, AS-3, or AS-5) for 42 days and then biochemically modified, frozen, thawed, washed, and stored at 4° C in sodium chloride and glucose solution for 24 hours," Transfusion, 40:1341-1345 (2000).
Wang et al., "Fabrication of PLGA microvessel scaffolds with circular microchannels using soft lithography," Journal of Micromechanics and Microengineering, 17(10):2000-2005 (2007).
Weinberg et al., "Transfusions in the Less Severely injured: Does Age of Transfused Blood Affect Outcomes?," The Journal of Trauma, 65(4):794-798 (2008).
Wilding et al., "Manipulation and Flow of Biological Fuids in Straight Channels Micromachined in Silicon," Clinical Chemistry, 40(1):43-47 (1994).
Wood et al., "The Viability of Human Blood Stored in Phosphate Adenine Media," Transfusion, 7(6):401-408 (1967).
Wu et al., "Polymer microchips bonded by O2-plasma activation," Electrophoresis, 23:782-790 (2002).
Yoshida et al., "Anaerobic storage of red blood cells," Blood Transfus, 8:220-236 (2010).
Yoshida et al., "Extended storage of red blood cells under anaerobic conditions," Vox Sanguinis, 92:22-31 (2007).
Yoshida et al., "Storage of red blood cells under anaerobic conditions: reply," Vox Sanguinis, 93:184 (2007).
Yoshida et al., "The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells," Transfusion, 48:2096-2105 (2008).
Zhang et al., "Modification of Si(100) surface by the grafting of poly(ethylene glycol) for reduction in protein adsorption and platelet adhesion," J Biomed Mater Res, 56:324-332 (2001).
Zimrin et al., "Current issues relating to the transfusion of stored red blood cells," Vox Sanguinis, 96:93-103 (2009).

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433164B2 (en) 2009-10-12 2022-09-06 Hemanext Inc. System for extended storage of red blood cells and methods of use
US9844615B2 (en) 2009-10-12 2017-12-19 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US10603417B2 (en) 2009-10-12 2020-03-31 Hemanext Inc. System for extended storage of red blood cells and methods of use
US10065134B2 (en) 2010-05-05 2018-09-04 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
US10136635B2 (en) 2010-05-05 2018-11-27 New Health Sciences, Inc. Irradiation of red blood cells and anaerobic storage
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US10251387B2 (en) 2010-08-25 2019-04-09 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
US9968718B2 (en) 2011-03-28 2018-05-15 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9814821B2 (en) * 2012-06-15 2017-11-14 University of Pittsburgh—of the Commonwealth System of Higher Education Devices, systems and methods for reducing the concentration of carbon dioxide in blood
US20150129493A1 (en) * 2012-06-15 2015-05-14 University of Pittsburgh-of The Commonweath System of Higher Education Devices, systems and methods for reducing the concentration of carbon dioxide in blood
US10687526B2 (en) 2013-02-28 2020-06-23 Hemanext Inc. Gas depletion and gas addition devices for blood treatment
US9877476B2 (en) 2013-02-28 2018-01-30 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
US10058091B2 (en) 2015-03-10 2018-08-28 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US11350626B2 (en) 2015-03-10 2022-06-07 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof (ORDKit)
US11375709B2 (en) 2015-03-10 2022-07-05 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US11638421B2 (en) 2015-03-10 2023-05-02 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US10849824B2 (en) 2015-04-23 2020-12-01 Hemanext Inc. Anaerobic blood storage containers
US9801784B2 (en) 2015-04-23 2017-10-31 New Health Sciences, Inc. Anaerobic blood storage containers
US11013771B2 (en) 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US11147876B2 (en) 2016-05-27 2021-10-19 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method
US10583192B2 (en) 2016-05-27 2020-03-10 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method
US11911471B2 (en) 2016-05-27 2024-02-27 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method
US11583615B2 (en) 2017-12-28 2023-02-21 I-Sep System and method for treating haemorrhagic fluid for autotransfusion
US11607478B2 (en) 2017-12-28 2023-03-21 I-Sep System and method for treating haemorrhagic fluid for autotransfusion

Also Published As

Publication number Publication date
NZ599890A (en) 2014-03-28
CA2781874A1 (en) 2011-04-21
BR112012008682A2 (en) 2017-06-20
WO2011046963A1 (en) 2011-04-21
JP2013507447A (en) 2013-03-04
EP2389064A1 (en) 2011-11-30
CN102905522A (en) 2013-01-30
US9296990B2 (en) 2016-03-29
EP2389064A4 (en) 2014-10-01
AU2010306920A1 (en) 2012-05-31
US20120100523A1 (en) 2012-04-26
US20140030694A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
US8569052B2 (en) Oxygen depletion devices and methods for removing oxygen from red blood cells
US8535421B2 (en) Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US10136635B2 (en) Irradiation of red blood cells and anaerobic storage
JP2019038852A (en) System for extended storage of red blood cells and methods of use
JP2017074381A (en) Method and system for depleting oxygen and carbon dioxide during red cell blood treatment using an inert carrier gas and manifold assembly
JP2013500794A (en) Oxygen removal from biological fluids
US11284616B2 (en) Irradiation of red blood cells and anaerobic storage
US20220211030A1 (en) Irradiation of Red Blood Cells and Anaerobic Storage

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEW HEALTH SCIENCES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOSHIDA, TATSURO;VERNUCCI, PAUL J.;REEL/FRAME:027505/0813

Effective date: 20120106

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEDERSPIEL, WILLIAM J.;FRANKOWSKI, BRIAN J.;REEL/FRAME:027506/0373

Effective date: 20120106

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8